The Effect of Periodic Examination Time Interval and Frequency After “Percutaneous Coronary Intervention” on Experiencing Second "Acute Coronary Syndrome"

Abstract

Objective: The aim of this study was to evaluate the effect of follow-ups of patients who underwent percutaneous coronary intervention (PCI) at short (<6 months) and long-term intervals and media on their experiencing attacks of acute coronary syndrome (ACS). Methods: The data of 281 patients who underwent twice PCI in our clinic were retrospectively analyzed. The patients were divided into two groups as those who came to the controls regularly at intervals of ≤ 6 months (Group 1, n: 157) and those who came irregularly or at intervals of more than 6 months (Group 2, n: 124). We investigated whether regular periodic controls have any positive effect on adequate statin use, experiencing acute coronary syndrome episodes and cardiac mortality. Results: In Group 2; frequency of ACS [87.8% versus 20.6%, p<0.001], insufficient use of statins [86.4% versus 16.7% p <0.001], and withdrawal of statins by media influence [64.0% versus 5.1% p <0.001] was higher than Group 1. Conclusions: Looking at the results of the study; it can be said that regular follow-up of patients with a cardiac event at 6-month intervals reduces the rate of acute coronary syndrome experience and treatment compliance is better in these people.

Keywords

• Acute Coronary Syndrome
• Angioplasty
• Follow-Up Studies
• Therapeutics Compliance

Project Number

yok

“Perkütan Koroner Girişim” Sonrası Periyodik Muayene Zaman Aralığı ve Sıklığının İkinci "Akut Koroner Sendrom" Yaşanmasına Etkisi

Abstract

Amaç: Bu çalışmayla perkütan koroner(PKG) girişim geçiren hastaların 6 aydan kısa ve uzun sürelerle kontrol edilmelerinin ve medyanın akut koroner sendrom(AKS) yaşamalarına etkisi araştırılmıştır. Gereç ve Yöntem: Kliniğimizde iki kez PKG geçirmiş 281 hastanın bilgileri retrospektif olarak incelenmiştir. Bu hastalar 6 ay ve daha kısa süreli düzenli takibe gelenler (Grup 1, n: 157) ve 6 aydan uzun sürelerle veya düzensiz takibe gelenler (Grup2, n: 124) ve olarak iki gruba ayrılmışlardır. Düzenli takiplerin yeterli statin kullanımında, akut koroner sendrom geçirmede ve kardiyak sebeple ölüm üzerinde etkili olup olmadığı araştırılmıştır. Bulgular: AKS sıklığı (87.8 e karşı 20.6% <0.001), yetersiz statin kullanım oranı[86.4 e karşı 16.7%, p<0.001], medyanın etkisiyle (%64.0 e karşı %5.1, p<0.001) statin kullanımını bırakanların oranı, Grup 2 de, Grup 1 den yüksek bulunmuştur. Sonuç: Çalışmanın sonuçlarına bakılınca; kardiyak olay yaşayan hastaların 6 ay aralarla düzenli takibe gelmelerinin, akut koroner sendrom yaşama oranlarını azalttığı ve tedavi uyumunun bu kişilerde daha iyi olduğu söylenebilir.

Keywords

• Akut koroner sendrom
• anjiyoplasti
• düzenli klinik takip
• tedavi uyumu

Supporting Institution

yok

Project Number

yok

References

1. [1]- French JK, Burgess S, Chew DP. Re-infarction after primary percutaneous coronary intervention. Curr Opin Cardiol. 2015; 30: 354-8.
2. [2]- Eyuboglu M. Survival after primary percutaneous coronary intervention. Int J Cardiol. 2016; 1: 202-953
3. [3]- Bromage DI, Jones DA, Rathod KS, Grout C, Iqbal MB. Outcome of 1051 Octogenarian Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Observational Cohort From the London Heart Attack Group. J Am Heart Assoc. 2016; 5: 6-6.
4. [4]- Şahi̇nkuş, S , Aksoy, M , Aydın, E , Eynel, E , Akçay, Ç , Kocayi̇ği̇t, İ , Can, Y , Kılıç, H , Akdemi̇r, R . "2018 Yılında Tek Merkezde Primer Perkutan Koroner Girişim Yapılan Hastaların Klinik Özellikleri, Anjiyografi İşleminin ve Hastane İçi Klinik Sonuçların Analizi". Sakarya Tıp Dergisi 10 (2020 ): 197-204
5. [5]- Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006; 333: 7578-1091.
6. [6]- Barindik, Uzun N, Baysan M, Kirilmaz O, Sağ A, Erinç C, Kiliçarslan K, Yokuşoğlu F, Genç M, Demirtaş C. Revaskülarizasyon yapılamayan semptomatik koroner arter hastalarında agresif lipid düşürücü tedavinin etkinliği / Effect of aggressive lipid lowering treatment in symptomatic coronary artery disease patients who are hot suitable for revascularization. Ertan Medical Network Kardiyoloji 2003,4:283-286
7. [7]- Task Force Members; Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 38: 2949-3003.
8. [8]- Galliver M. “Media coverage of statins may have led to 2000 cardiovascular events.” BMJ. 2016 Jun 30;353.

9. [9]- Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001; 104: 2746-53. [10]- Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133: 776S-814.
10. [11]- Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003; 138: 161-7.
11. [12]- Brener SJ, Weisz G, Maehara A, Mehran R, McPherson J, Farhat N, et al. Does clinical presentation affect outcome among patients with acute coronary syndromes undergoing percutaneous coronary intervention? Insights from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree study. Am Heart J. 2012; 164 : 561-7
12. [13]- Ricciardi MJ, Selzer F, Marroquin OC, Holper EM, Venkitachalam L, Williams DO, et al. Incidence and predictors of 30-day hospital readmission rate following percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol. 2012; 110 : 1389-96.
13. [14]- Rallidis LS, Kiouri E, Katsimardos A, Kotakos C. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL.Atherosclerosis. 2018; 275 : 262-264.
14. [15]- Yebyo HG, Aschmann HE, Puhan MA. “Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study.” Ann Intern Med. 2018 Dec 4. doi: 10.7326/M18-1279.
15. [16]- Dinç M, Abul Y "Kronik Hastalıklarda Kontrol ve Takip Düzeni(Control and Follow-Up Arrangement in Chronic Diseases)" Turkiye Klinikleri J Fam Med-Special Topics 2013; 4 : 107-11.
16. [17]- Matthews A, Herrett E, Gasparrini A, Van Staa T, Goldacre B, Smeeth L, Bhaskaran K. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. BMJ. 2016 Jun 28; 353: 3283.
17. [18]- Dincer G, Alsancak Z; Alsancak Y; Gümüş E; Tekin O. Patient compliance to statin treatment: how effective is the media? Turkish Journal of Family Practice / Türkiye Aile Hekimligi Dergisi. 2016; 20: 23-28.
18. [19]- Yalçın Aa, Bıyık İ,Aktürk İf, Çelik Ö, Özbay S, Özyılmaz Sö, Burçe Yalçın B, Hançer Vs, Taşbulak Ö, Öztürk D, Uzun F. Etkili İkili Antiplatelet Tedavi Altındaki Hastalarda Akut Stent Trombozu Gelişiminde Endotelyal Nitrik Oksit Sentaz Glu298asp Gen Polimorfizminin Rolünün Değerlendirilmesi. Türk Girişimsel Kardiyoloji Dergisi - 2014; 18: 65-73.
19. [20]- Şimşek V. New Concepts in ST Elevation Myocardial Infarction in 2017 2017 ST Yükselmeli Miyokart Enfarktüsü Kılavuzunda Yenilikler. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi 2017; 19: 214-219.